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AnxietyCa2+-dependent activator protein for secretion 2 (CAPS2 or CADPS2) facilitates secretion and traf-
ﬁcking of dense-core vesicles. Recent genome-wide association studies of autism have identiﬁed
several microdeletions due to copy number variation (CNV) in one of the chromosome 7q31.32
alleles on which the locus for CAPS2 is located in autistic patients. To evaluate the biological signif-
icance of reducing CAPS2 copy number, we analyzed CAPS2 heterozygous mice. Our present ﬁndings
suggest that adequate levels of CAPS2 protein are critical for normal brain development and behav-
ior, and that allelic changes due to CNV may contribute to autistic symptoms in combination with
deﬁcits in other autism-associated genes.
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Autism is a severe neurodevelopmental disorder marked by
profound disturbances in social, communicative, and behavioral
functioning [1,2]. Epidemiological studies have shown that the
prevalence of autism spectrum disorders is 3–6 per 1000, with a
male-to-female ratio of 3:1 [3]. The concordance rate in monozy-
gotic twins is about 90%, whereas that in dizygotic twins is 10%
[4], suggesting that autism has a prominent genetic component.
Recent genetic and genomic studies have identiﬁed a large number
of candidate genes for autism [5], many of which encode proteins
related to the formation or function of synapses, indicating that
synaptic dysfunction may play a critical role in autism [6–12].
The Ca2+-dependent activator protein for secretion (CAPS/CAD-
PS) family consists of two family members, CAPS1 [13] and CAPS2,
in mammals [14,15]. Previous studies have indicated that CAPS is
involved in the trafﬁcking of dense-core vesicles (DCVs) duringtheir exocytosis [13,16–18]. The human CAPS2 gene maps to hu-
man chromosome 7q31.32 [19], which is located within a suscep-
tibility locus for autism, 7q31–q33, named the autism
susceptibility locus 1 (AUTS1) [20]. Mouse CAPS2 protein is immu-
nohistochemically co-localized with brain-derived neurotrophic
factor (BDNF) throughout various brain regions [21] and is associ-
ated with BDNF-containing secretory vesicles [15]. BDNF is activ-
ity-dependently released from neurons [22–25] and plays a key
role in many aspects of brain development and function, including
the formation of synapses and circuits [26,27]. CAPS2 is involved in
the activity-dependent release of BDNF [15] and promotes its
secretion kinetics [28]. Moreover, a study of CAPS2 in autism
showed that a subgroup of autistic patients expresses aberrant
exon 3-skipped CAPS2 that is not properly transported into axons,
presumably resulting in a deﬁcit in local synaptic BDNF release
[29]. In addition, seven non-synonymous single-nucleotide varia-
tions of the CAPS2 gene were identiﬁed in patients with autism
[29]. Therefore, we hypothesized that CAPS2 is a candidate autism
susceptibility gene [29,30]. Recent genome-wide association stud-
ies have shown the presence of several microdeletions within
7q31.32, including the CAPS2 locus, in single alleles of autistic pa-
tients [31,32]. Moreover, it was recently suggested that transcrip-
tional and splicing dysregulation are the mechanisms underlying
neuronal dysfunction in patients with autism [33]. In that report,
Voineagu and colleagues showed decreased transcription of CAPS2
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transcription of the CAPS2 gene are unknown.
In this report, we examined the effects of the loss of the CAPS2
gene from one allele on behavioral phenotypes by utilizing CAPS2
heterozygous mice expected to be equivalent to patients with a
copy number reduction and decreased transcription. We found
that CAPS2 heterozygotes showed impairments in adaptation to a
novel environment, ultrasonic vocalization (USV) and circadian
behavior, suggesting that reduction of CAPS2 expression partly
contributes to the onset of autistic-like symptoms.
2. Materials and methods
2.1. Behavioral tests
Breeding and all tests were basically performed as described in
a previous study [29]. Brieﬂy, mice were housed with a 12:12 h
light–dark cycle, with the dark cycle occurring from 20:00 to
8:00. All mice used in the experiments below were littermates
from mated heterozygotes unless otherwise noted. The experi-
menter was blind to the genotype in all behavioral tests.
2.1.1. Open ﬁeld test and novel object recognition test
The test was performed as previously described [34,35] with
minor modiﬁcations. Two-month-old male mice were used. Loco-
motor activity was measured with an open ﬁeld apparatus
(60  60 cm) at 50 lux (at the surface level of the area). Each mouse
was placed in the center of the open ﬁeld, and its horizontal move-
ments were monitored for 15 min with a video camera. The images
were processed using NIH IMAGE O.F. software (O’Hara & Co.,
Tokyo, Japan). Total activity was used in the statistical analysis.
2.1.2. Vocalization
Ultrasonic vocalization (USV) was monitored before behavioral
testing between P5 and P7. Wild-type females were mated with
wild-type or homozygote males. The pups in the home cage were
separated from their dam immediately before recording and were
positioned in the sound-attenuating chamber below a Condenser
Ultrasound Microphone (cat. No. 40011, Avisoft Bioacoustics) to
detect USVs at 50–100 kHz. The number of calls was recorded
and quantiﬁed using Avisoft-RECORDER software (Avisoft Bio-
acoustics). Call frequency was measured as the number of USVs
an animal made during the 10-min test.
2.1.3. Recording of circadian rhythms
The circadian rhythms were recorded as previously described
[36]. Two-month-old male mice were used. Wheel-running was
measured using a wheel-meter (WW-3302, O’Hara & Co.) with
20 sets of a room (14.3 cm wide  14.8 cm high  29.3 cm deep)
and a wheel-cage (50 cm lap  5 cmwide). Mice were able to move
freely and given free access to solid food and water. Every 1/3 rev-
olution of the wheel-cage was recorded as 1 count. The circadian
period was calculated using the chi-square periodogram.
Other methods are provided in the Supplementary data.3. Results
Fig. 1A shows the region of two different microdeletions re-
ported in autistic patients [31,32]. One of the deletions (del-1,
748 kb) almost corresponds to the entire region of the CAPS2 gene.
Thus, we thought that CAPS2 heterozygous mutant mice would be
almost equivalent to patients with the del-1 microdeletion with re-
spect to any dosage effect (= copy number) of the CAPS2 gene. We
ﬁrst examined the expression levels of CAPS2 protein in the brains
of heterozygous mice by western blotting. Heterozygous miceshowed a reduced intensity of CAPS2-immunopositive bands in
protein extracts from the cerebellum, hippocampus and neocortex
(Fig. 1B and C), indicating that heterozygous mice have reduced
CAPS2 protein levels in the brain.
To investigate the effect of decreased CAPS2 protein on BDNF
secretion, we examined constitutive and regulated BDNF release
from primary cell cultures of wild-type and heterozygous mice.
We exogenously overexpressed BDNF in cerebellar cultures at 5
DIV using a recombinant adenoviral vector [15]. In this system,
granule cells, which are the predominant cell type expressing
CAPS2 in mouse cerebellum [15,21], are preferentially infected
with the adenovirus vector [37]. At 48 h after infection with the
adenovirus vector, cultures expressing either BDNF-GFP (Ad-
BDNF-GFP) or GFP alone (Ad-GFP) at 7 DIV were treated for
15 min with media containing 5 mM KCl as a control, or 50 mM
KCl to induce membrane depolarization. BDNF secretion from het-
erozygous cultures was decreased compared with that from wild-
type cultures by both 5 mM KCl and 50 mM KCl media (Fig. 1D).
These results suggest that a decrease in CAPS2 protein affects both
constitutive and regulated BDNF release from cerebellar dissoci-
ated cultures.
We then examined the behavioral phenotypes of CAPS2 het-
erozygous mice. We used male mice for the analyses of behavior
except for the analysis of maternal behavior. CAPS2 heterozygous
mice placed in an open ﬁeld in the light cycle showed normal
locomotor activity (Fig. 2A) and speed (Fig. 2B) in comparison
with their wild-type littermates. There was no signiﬁcant differ-
ence between wild-type and CAPS2 heterozygous mice in terms
of the time spent in a central area (Fig. 2C), which is generally ac-
cepted as a measure of fear in rodents [38]. However, as shown in
Fig. 2D, CAPS2 heterozygous mice became less active than wild-
type mice when placed in an open ﬁeld containing a novel object
(the black-and-white vertical object shown in the inset of Fig. 2D)
at its center (3958.1 ± 181.7 cm in wild-type vs.
3071.7 ± 217.4 cm in CAPS2 heterozygotes, mean ± SEM,
P = 0.0053, by Student’s t-test). Moreover, CAPS2 heterozygous
mice showed decreased speed in comparison with their wild-type
littermates (4.40 ± 0.20 cm/s in wild-type vs. 3.42 ± 0.24 cm/s in
CAPS2 heterozygotes, mean ± SEM, P = 0.0052, by Student’s t-test)
(Fig. 2E). However, there was no signiﬁcant difference in the time
spent in a central area between wild-type and CAPS2 heterozy-
gous mice (Fig. 2F).
We next administered elevated plus maze tests. There was no
difference in moving distance, suggesting that locomotor activity
was not affected by the decrease in the level of CAPS2 protein
(Fig. 3A). There was also no difference in time spent in the open
and closed arms of the apparatus (Fig. 3B, C). In addition, the
number of open arm entries was not decreased (data not
shown).
A light/dark box experiment was also carried out (Fig. 3D–F).
There were no differences in anxiety-like behavior, as measured
in the light/dark box experiment for distance (Fig. 3D), in time
spent in the light portion of the box (Fig. 3E), or in the latency to
transition between the light and dark portions (Fig. 3F).
Next, social interaction tests were performed. Wild-type and
CAPS2 heterozygous mice were placed in the center of an open
ﬁeld. Another C57BL/6J mouse in a small cage was placed in the
corner of the open ﬁeld. CAPS2 heterozygous mice placed in an
open ﬁeld showed normal locomotor activity (Fig. 4A) and speed
(Fig. 4B). Moreover, there was no difference between wild-type
and CAPS2 heterozygous mice in the time spent interacting with
the small cage containing the unfamiliar mouse (Fig. 4C). In a con-
trol experiment, we found that there was also no difference be-
tween wild-type and CAPS2 heterozygous mice in the time spent
interacting with an empty small cage (i.e. not containing an unfa-
miliar mouse) (data not shown).
Fig. 1. CAPS2 gene dosage effect. (A) Microdeletions around the CAPS2 gene locus were identiﬁed in two autistic patients. The left bar (del-1) is the case reported by Stazmari
et al. (2007), and the right bar (del-2) is that reported by Christian et al. (2008). (B) Immunoblot analysis of the neocortex, hippocampus, and cerebellum of P15 wild-type (+/
+), CAPS2 heterozygous (+/), and homozygous (/) mice. Protein lysates were immunoblotted with anti-CAPS2 (left panel) and anti-actin (right panel) antibodies. (C)
Expression levels of CAPS2 protein in the cerebellum of +/+, +/, and /mice. The graph shows average CAPS2 expression levels from ﬁve different experiments. The band
intensity of the CAPS2 protein by western blot analysis of P15 cerebellum was normalized with respect to the intensity of the actin band. Ten micrograms of cell lysate were
electrophoresed in each lane. P < 0.05, one-factor ANOVA. (D) BDNF secretion assay of +/+ and +/ cerebellar primary cultures. Cerebellar primary cultures from +/+ (white
bars) and +/ (gray bars) mice were infected with adenovirus (Ad) vectors, either Ad-GFP or Ad-BDNF-GFP, at 5 DIV. BDNF secretion assays were performed at 7 DIV by
stimulating the cultures with either 5 mM KCl- or 50 mM KCl-containing secretion assay media for 15 min followed by ELISA of BDNF released into the media. Average values
obtained from four independent experiments are shown. BDNF concentration (pg/ll) was normalized to the MAP2ab-positive cell number. The error bars indicate the SEM.
⁄⁄P < 0.01, by Student’s t-test.
Fig. 2. CAPS2-heterozygous mice tend to show decreased exploratory behavior in a novel environment. Horizontal movement distance (A, D), speed (B, E), and center time (C,
F) for +/+ (white; n = 11) and +/ (grey; n = 11) mice in an open ﬁeld (15 min) are shown in the absence (A–C) or presence (D–F) of a novel object shown in the inset of (D). The
error bars indicate the SEM. ⁄⁄P < 0.01, by Student’s t-test.
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production, we studied USVs of neonates using CAPS2
heterozygous mice. The total number of USVs was reduced in
CAPS2 heterozygous pups (Fig. 4D). A developmental analysis ofUSVs showed that total USVs decreased in the early
postnatal stage. Therefore, the decrease in the level of
CAPS2 protein affects the dam–pup interaction associated
USVs.
Fig. 3. Anxiety-like behavior of CAPS2 heterozygous mice. (A–C) Horizontal movement distance (A), time spent in open arms (B) and time spent in closed arms (C) of +/+
(white; n = 12) and +/ (black; n = 12) during a 10-min test in an elevated plus maze are shown. (D–F) Horizontal movement distance (D), time spent in the dark box (E), and
latency to transition to the light box (F) of +/+ (white; n = 12) and +/ (grey; n = 12) during a 10-min test in a light/dark box are shown. The error bars indicate the SEM.
Fig. 4. Social behavior of CAPS2 heterozygous mice. (A) Each mouse was placed into the open ﬁeld apparatus for 15 min. A small cage containing a stranger B6j mouse was
placed in its corner. Representative movement traces are shown. Interaction areas are shown with black squares. Horizontal movement distance (A), speed (B), and time spent
in the interaction area (C) of +/+ (white; n = 12) and +/ (grey; n = 12) are shown. (D) The total USVs per pups were reduced in CAPS2 heterozygous mice. Wild-type females
were mated with wild-type males or CAPS2 homozygous males. The pups in the home cage were separated from their dam immediately before recordings and used for USV
experiments. The developmental changes in USVs in +/+ (open circles; n = 7 litters) and +/ (closed circles; n = 8 litters) pups are shown. The error bars indicate the SEM.
⁄P < 0.05, Mann–Whitney U test.
Fig. 5. Abnormal sleep–wake rhythm of CAPS2 heterozygous mice. (A and B) Activity traces of +/+ (A) and +/ (B) mice for 3 days of LD cycle and 6 days of constant darkness
(DD) are represented as relative deﬂections from the horizontal line. Actograms are double-plotted over a 48-h period. (C) Sleep–wake rhythms of locomotor activity under
free wheel-running conditions in the DD cycle. The circadian periods (h) of +/+ (white; n = 12) and +/ (grey; n = 11) calculated by a chi-square periodogram. The error bars
indicate the SEM. ⁄⁄P < 0.01, by Student’s t-test.
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sleep–wake regulation and circadian rhythmicity (Fig. 5). When
the circadian rhythm of locomotor activity was recorded under a
12:12 h light–dark (LD) cycle, no difference in sleep–wake rhythmwas detected between wild-type and CAPS2 heterozygous mice
(Fig. 5A and 5B). Under constant dark (DD) conditions, the sleep–
wake rhythm of wild-type mice shifted to a shorter period than un-
der LD conditions (Fig. 5A), because the internal circadian period of
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exhibited a different (longer than wild-type) intrinsic rhythmicity
under DD conditions (Fig. 5B and 5C).
4. Discussion
We previously demonstrated that CAPS2 homozygous mice ex-
hibit impaired behavioral phenotypes (decreased social interac-
tion, hyperactivity, decreased exploratory behavior and increased
anxiety in a novel unfamiliar environment, disturbed intrinsic
sleep and awake rhythms), which are reminiscent of the behaviors
of patients with autism [29]. In the present study, we examined the
phenotypes of CAPS2 heterozygous mice with one copy of the
CAPS2 gene. CAPS2 heterozygous mice tended to show decreased
locomotion activity in a more novel environment, in which mice
encountered an unfamiliar object placed at the center of an
open-ﬁeld area. There was no signiﬁcant difference in anxious
behavior between wild-type and heterozygous mice in elevated
plus maze tests and light/dark transition tests. Thus, these results
suggest that decreased locomotion in a more novel environment
is not simply attributable to increased anxiety intrinsic to CAPS2
heterozygotes. We observed no difference between wild-type and
CAPS2 heterozygous mice in social-like behavior to communicate
with an unfamiliar mouse. However, USVs emitted by pups, which
are probably related to the interaction between pups and their
dams, were decreased in CAPS2 heterozygous pups. Moreover,
CAPS2 heterozygous mice showed deﬁcits in intrinsic sleep–wake
regulation and circadian rhythmicity.
In a previous report, both CAPS2 heterozygous and homozygous
mice showed decreased locomotor activity in a novel environment
[29]. CAPS2 homozygote mice made signiﬁcantly fewer contacts
with a novel object than wild-type mice did [29], whereas there
was no signiﬁcant difference in the time spent in a central area be-
tween wild-type and CAPS2 heterozygote mice. Moreover, CAPS2
homozygotes showed impaired social behavior [29], whereas a so-
cial interaction test revealed no difference between wild-type and
CAPS2 heterozygous mice. In contrast, CAPS2 heterozygote mice
showed deﬁcits in intrinsic sleep–wake regulation and circadian
rhythm under constant dark conditions, as do CAPS2 homozygote
mice [29]. It is possible that the dependency of BDNF release activ-
ity on the amount of CAPS2 protein, shown in a previous report
[29], results in this behavioral difference between heterozygote
and homozygote mice.
In conclusion, to address the question of whether a reduction in
the copy number of the CAPS2 gene is associated with the onset of
autistic symptoms, we analyzed the biological aspects of CAPS2
gene dosage effects by utilizing CAPS2 heterozygous mice. The level
of CAPS2 protein in CAPS2 heterozygous mice was reduced to
approximately half of that in wild-type mice. This reduction in
the level of CAPS2 protein caused decreased activity in a more no-
vel environment, but did not signiﬁcantly affect social behavior, in
contrast to the phenotypes caused by complete deletion of CAPS2
in homozygote mice [29]. On the other hand, the amounts of ultra-
sonic calls emitted by pups, which are probably involved in the
dam–pup interaction, were decreased in CAPS2 heterozygous pups.
Moreover, the CAPS2 heterozygous mice showed deﬁcits in intrin-
sic sleep–wake regulation and circadian rhythmicity. Together,
these results suggest that CAPS2 protein levels are critical to nor-
mal brain development and behavior, and partly affect susceptibil-
ity to some symptoms in autistic patients that have copy number
variations/decreased transcription of the CAPS2 gene. Although
not capable of causing autism on their own, changes in CAPS2 lev-
els may exacerbate autistic symptoms when occurring against a
background of pro-autistic environmental conditions and/or
impairment of other autism-associated gene products.Acknowledgments
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